ArticleProceedings of the National Academy of Sciences of the United States of America2017

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.

Stephen E Kurtz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.